{"meshTags":["Trastuzumab","Chemotherapy, Adjuvant","Thrombotic Microangiopathies","Middle Aged","Antineoplastic Combined Chemotherapy Protocols","Female","Breast Neoplasms","Antibodies, Monoclonal, Humanized","Carboplatin","Taxoids","Humans","Receptor, ErbB-2"],"meshMinor":["Trastuzumab","Chemotherapy, Adjuvant","Thrombotic Microangiopathies","Middle Aged","Antineoplastic Combined Chemotherapy Protocols","Female","Breast Neoplasms","Antibodies, Monoclonal, Humanized","Carboplatin","Taxoids","Humans","Receptor, ErbB-2"],"organisms":["9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"Chemotherapy-induced thrombotic microangiopathy is a severe illness that has occurred in a small number of patients treated with carboplatin and combination of docetaxel and trastuzumab chemotherapy. We describe herein the case of a patient with stage IIB breast cancer who developed thrombotic microangiopathy after five cycles of carboplatin, docetaxel, and trastuzumab.","title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.","pubmedId":"23564368"}